BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions ...
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...
Under the 'NIOS Project,' an average of 70 per cent of students who took the 10th grade examination have failed in the last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback